These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 18723329)

  • 1. New antibiotic agents for bloodstream infections.
    Vergidis PI; Falagas ME
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections.
    Del Pozo JL; Alonso M; Serrera A; Hernaez S; Aguinaga A; Leiva J
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):208-12. PubMed ID: 19026506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs.
    Grossi PA
    Int J Antimicrob Agents; 2009; 34 Suppl 4():S31-4. PubMed ID: 19931814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK
    Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antibiotics: optimal use in current clinical practice.
    Karageorgopoulos DE; Falagas ME
    Int J Antimicrob Agents; 2009; 34 Suppl 4():S55-62. PubMed ID: 19931821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis.
    Pai AB; Pai MP
    Adv Chronic Kidney Dis; 2006 Jul; 13(3):259-70. PubMed ID: 16815231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections.
    Kunz AN; Brook I
    Chemotherapy; 2010; 56(6):492-500. PubMed ID: 21099222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antibiotics for the management of diabetic foot infections.
    Omar NS; El-Nahas MR; Gray J
    Int J Antimicrob Agents; 2008 May; 31(5):411-9. PubMed ID: 18155884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
    Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
    J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin: use beyond urinary tract and gastrointestinal infections.
    Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI
    Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant bacteria in hospitalized children: a 5-year multicenter study.
    Raymond J; Nordmann P; Doit C; Vu Thien H; Guibert M; Ferroni A; Aujard Y
    Pediatrics; 2007 Apr; 119(4):e798-803. PubMed ID: 17403822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of serious nosocomial bacterial infections: do current therapeutic options meet the need?
    Lode H
    Clin Microbiol Infect; 2005 Oct; 11(10):778-87. PubMed ID: 16153251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of antibiotic resistance in the intensive care unit setting.
    Petrosillo N; Capone A; Di Bella S; Taglietti F
    Expert Rev Anti Infect Ther; 2010 Mar; 8(3):289-302. PubMed ID: 20192683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of gram-positive coccal bacteremia and hemodialysis.
    Fitzgibbons LN; Puls DL; Mackay K; Forrest GN
    Am J Kidney Dis; 2011 Apr; 57(4):624-40. PubMed ID: 21333430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and management of Gram-positive bacteraemia.
    Cervera C; Almela M; Martínez-Martínez JA; Moreno A; Miró JM
    Int J Antimicrob Agents; 2009; 34 Suppl 4():S26-30. PubMed ID: 19931813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Gram-positive bacteraemia.
    Uçkay I; Harbarth S; Pittet D
    Curr Opin Infect Dis; 2007 Dec; 20(6):561-7. PubMed ID: 17975404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.